Novel study of UK real-world data reveals almost 500,000 people missed out on starting antihypertensive medications during the COVID-19 pandemic

An investigation of cardiovascular disease prevention and management through innovative analysis of real-world data (RWD) has shown that nearly 500,000 people in Great Britain missed out on starting antihypertensive medications during the COVID-19 pandemic.   A new study published in Nature Medicine is the first to use mass analysis of RWD to track the nationwide management of a major chronic health condition, in this case, cardiovascular disease (CVD). Using data on routinely dispensed prescriptions in England, Scotland and Wales, researchers found that almost half a million fewer people than expected started taking antihypertensive treatments during the COVID-19 pandemic. The study...